Nang Kuang Pharmaceutical Co., Ltd. (1752.TW)
TWD 35.5
(1.0%)
TWD 35.5
(1.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 198.4 Million TWD | -43.63% |
| 2022 | 351.99 Million TWD | 79.49% |
| 2021 | 196.11 Million TWD | 6.93% |
| 2020 | 183.39 Million TWD | -15.66% |
| 2019 | 217.44 Million TWD | 114.79% |
| 2018 | 101.23 Million TWD | -45.52% |
| 2017 | 185.81 Million TWD | -17.6% |
| 2016 | 225.49 Million TWD | 13.32% |
| 2015 | 198.98 Million TWD | 195.75% |
| 2014 | 67.28 Million TWD | 960.6% |
| 2013 | -7.81 Million TWD | -109.73% |
| 2012 | 80.37 Million TWD | 1204.35% |
| 2011 | 6.16 Million TWD | 158.21% |
| 2010 | -10.58 Million TWD | -188.68% |
| 2009 | 11.93 Million TWD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 54.69 Million TWD | 257.18% |
| 2024 Q2 | 44.13 Million TWD | -19.3% |
| 2023 Q4 | -34.79 Million TWD | -174.63% |
| 2023 Q3 | 46.62 Million TWD | -49.66% |
| 2023 FY | 198.4 Million TWD | -43.63% |
| 2023 Q1 | 93.96 Million TWD | -41.91% |
| 2023 Q2 | 92.61 Million TWD | -1.44% |
| 2022 Q1 | 41.02 Million TWD | -20.56% |
| 2022 FY | 351.99 Million TWD | 79.49% |
| 2022 Q4 | 161.77 Million TWD | 116.84% |
| 2022 Q3 | 74.6 Million TWD | -0.01% |
| 2022 Q2 | 74.6 Million TWD | 81.88% |
| 2021 Q4 | 51.63 Million TWD | 13.66% |
| 2021 Q1 | 44.78 Million TWD | -6.08% |
| 2021 Q2 | 54.26 Million TWD | 21.16% |
| 2021 FY | 196.11 Million TWD | 6.93% |
| 2021 Q3 | 45.43 Million TWD | -16.27% |
| 2020 Q3 | 29.38 Million TWD | -32.24% |
| 2020 Q2 | 43.36 Million TWD | -31.12% |
| 2020 Q4 | 47.68 Million TWD | 62.27% |
| 2020 Q1 | 62.96 Million TWD | -21.6% |
| 2020 FY | 183.39 Million TWD | -15.66% |
| 2019 Q4 | 80.3 Million TWD | 32.88% |
| 2019 Q2 | 41.24 Million TWD | 16.35% |
| 2019 Q1 | 35.45 Million TWD | 50.94% |
| 2019 FY | 217.44 Million TWD | 114.79% |
| 2019 Q3 | 60.43 Million TWD | 46.52% |
| 2018 FY | 101.23 Million TWD | -45.52% |
| 2018 Q4 | 23.48 Million TWD | 136.81% |
| 2018 Q3 | 9.91 Million TWD | -67.0% |
| 2018 Q2 | 30.05 Million TWD | -20.43% |
| 2018 Q1 | 37.77 Million TWD | -26.52% |
| 2017 FY | 185.81 Million TWD | -17.6% |
| 2017 Q4 | 51.4 Million TWD | 52.19% |
| 2017 Q3 | 33.77 Million TWD | -4.87% |
| 2017 Q1 | 65.12 Million TWD | -4.53% |
| 2017 Q2 | 35.5 Million TWD | -45.48% |
| 2016 FY | 225.49 Million TWD | 13.32% |
| 2016 Q4 | 68.21 Million TWD | 63.32% |
| 2016 Q3 | 41.76 Million TWD | -16.44% |
| 2016 Q2 | 49.98 Million TWD | -23.73% |
| 2016 Q1 | 65.53 Million TWD | 19.59% |
| 2015 Q2 | 44.2 Million TWD | 19.25% |
| 2015 Q3 | 62.91 Million TWD | 42.33% |
| 2015 Q4 | 54.79 Million TWD | -12.9% |
| 2015 FY | 198.98 Million TWD | 195.75% |
| 2015 Q1 | 37.06 Million TWD | -15.2% |
| 2014 Q3 | 28.45 Million TWD | 48965.52% |
| 2014 Q1 | -4.94 Million TWD | -20.44% |
| 2014 FY | 67.28 Million TWD | 960.6% |
| 2014 Q4 | 43.71 Million TWD | 53.61% |
| 2014 Q2 | 58 Thousand TWD | 101.17% |
| 2013 Q2 | -7.9 Million TWD | -559.71% |
| 2013 Q4 | -4.1 Million TWD | -265.82% |
| 2013 FY | -7.81 Million TWD | -109.73% |
| 2013 Q1 | 1.72 Million TWD | -80.39% |
| 2013 Q3 | 2.47 Million TWD | 131.34% |
| 2012 Q1 | 20.1 Million TWD | 2195.43% |
| 2012 Q2 | 28.68 Million TWD | 42.67% |
| 2012 FY | 80.37 Million TWD | 1204.35% |
| 2012 Q3 | 23.54 Million TWD | -17.92% |
| 2012 Q4 | 8.77 Million TWD | -62.75% |
| 2011 Q2 | -4.82 Million TWD | -136.63% |
| 2011 Q1 | 13.16 Million TWD | 375.99% |
| 2011 Q4 | 876 Thousand TWD | 128.67% |
| 2011 Q3 | -3.05 Million TWD | 36.63% |
| 2011 FY | 6.16 Million TWD | 158.21% |
| 2010 Q3 | 6.55 Million TWD | 600.61% |
| 2010 Q2 | -1.3 Million TWD | 88.16% |
| 2010 Q1 | -11.06 Million TWD | 0.0% |
| 2010 Q4 | -4.76 Million TWD | -172.78% |
| 2010 FY | -10.58 Million TWD | -188.68% |
| 2009 FY | 11.93 Million TWD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Maxigen Biotech Inc. | 165.82 Million TWD | -19.647% |
| SciVision Biotech Inc. | 177.9 Million TWD | -11.528% |
| Bionime Corporation | 6.2 Million TWD | -3095.507% |
| Pegavision Corporation | 1.65 Billion TWD | 88.018% |
| Visco Vision Inc. | 301.61 Million TWD | 34.217% |